Mizuho Raises Cardinal Health Price Target to $250 Amid Strong Earnings
Wed, August 19, 2026Mizuho Raises Cardinal Health Price Target to $250 Amid Strong Earnings
On August 12, 2026, Mizuho Securities raised its price target for Cardinal Health (NYSE: CAH) to $250 from $240, maintaining an “Outperform” rating. This adjustment follows Cardinal Health’s robust fourth-quarter fiscal 2026 earnings report. The stock is currently trading at $234.98, reflecting a 66% increase over the past year and nearing its 52-week high of $258.30.
Analyst Insights and Earnings Highlights
Mizuho’s decision was influenced by Cardinal Health’s strong performance in the fourth quarter of fiscal 2026. The company’s management highlighted significant brand-to-generic conversion activity during the second calendar quarter of 2026, with over $20 billion in new generic launches. This strategic focus on generics is expected to enhance profitability and market share.
Financial Performance and Market Position
As of August 18, 2026, Cardinal Health’s stock price stands at $234.98, with a market capitalization of approximately $55.88 billion. The company’s trailing twelve months (TTM) revenue is $254.25 billion, and its net income available to common shareholders is $1.71 billion, resulting in a diluted EPS of $7.23. These figures underscore the company’s strong financial health and its ability to generate consistent earnings.
Analyst Perspectives
The positive outlook from Mizuho aligns with other analysts’ views. For instance, Morgan Stanley previously raised its price target for Cardinal Health to $255 from $245, maintaining an “Overweight” rating. Such endorsements reflect confidence in the company’s strategic direction and financial performance.
Conclusion
Mizuho’s increased price target for Cardinal Health highlights the company’s strong earnings performance and strategic initiatives, particularly in the generic pharmaceuticals sector. With a solid financial foundation and positive analyst sentiment, Cardinal Health appears well-positioned for continued growth in the integrated healthcare services and products industry.